BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced that hemophilia A gene therapy clinical data and hemoglobinopathies ex vivo gene-edited cell therapy data will be featured in poster presentations at the 61st Annual Meeting of the American Society of Hematology (ASH). The ASH abstracts, which were submitted on August 3, 2019, were released online this morning. The conference will take place in Orlando, FL, from December 7-10, 2019.
The SB-525 poster will show updated Alta study data including durability of Factor VIII (FVIII) levels, bleeding rate, factor usage, and safety, for all five patients in the high dose cohort of 3e13 vg/kg, with approximately 4 months to 11 months of follow-up after treatment with SB-525.
As of the abstract submission date, four patients in the 3e13 vg/kg cohort achieved FVIII levels within the normal range with no bleeding events reported up to 24 weeks post-administration. These patients did not require FVIII replacement therapy following the initial prophylactic period of up to approximately 3 weeks post-SB-525 administration. The fifth patient in the 3e13 vg/kg cohort had only recently undergone treatment with SB-525 at the time of the abstract submission. As previously reported, one patient had treatment-related serious adverse events (SAEs) of hypotension and fever, which occurred approximately 6 hours after completion of the vector infusion and resolved with treatment within 24 hours, with no loss of FVIII expression. SB-525 is being developed as part of a global collaboration between Sangamo and Pfizer.
The rapid kinetics of Factor VIII expression, durability of response, and the relatively low intra-cohort variability in the context of a complete cessation of bleeding events and elimination of exogenous Factor VIII usage continues to suggest SB-525 is a differentiated hemophilia A gene therapy, said Bettina Cockroft, M.D., M.B.A., Chief Medical Officer of Sangamo, commenting on the published abstract. We are pleased with the progress of the program toward a registrational Phase 3 study led by Pfizer, who announced it has enrolled its first patient in the 6-month Phase 3 lead-in study. We have recently completed the manufacturing technology transfer to Pfizer and initiated the transfer of the IND.
Ex Vivo Gene-Edited Cell Therapy
The ST-400 beta thalassemia poster will show preliminary results from the first three patients enrolled in the Phase 1/2 THALES study. In this study, hematopoietic stem progenitor cells (HSPCs) are apheresed from the patient, edited to knock out the erythroid specific enhancer of the BCL11A gene, and cryopreserved prior to infusion back into the patient following myeloablative conditioning with busulfan. The first three patients all have severe beta thalassemia genotypes: 0/0, homozygous for the severe + IVS-I-5 (G>C) mutation, and 0/+ genotype including the severe IVS-II-654 (C>T) mutation, respectively.
As of the abstract submission date, Patient 1 and Patient 2 had experienced prompt hematopoietic reconstitution. Patient 1 had increasing fetal hemoglobin (HbF) fraction that contributed to a stable total hemoglobin. After being free from packed red blood cell (PRBC) transfusions for 6 weeks, the patient subsequently required intermittent transfusions. Patient 2 had rising HbF levels observed through 90 days post-infusion. For both patients, as of the most recent follow-up reported in the abstract, on-target insertions and deletions (indels) were present in circulating white blood cells. Patient 3 had just completed ST-400 manufacturing at the time of abstract submission. As previously disclosed, Patient 1 experienced an SAE of hypersensitivity during ST-400 infusion considered by the investigator to be related to the product cryoprotectant, DSMO, and which resolved by the end of the infusion. No other SAEs related to ST-400 have been reported and all other AEs have been consistent with myeloablation. No clonal hematopoiesis has been observed. Longer follow-up will be required to assess the clinical significance of these early results. ST-400 is being developed as part of a global collaboration between Sangamo and Sanofi, along with support through a grant from the California Institute for Regenerative Medicine (CIRM).
The first three patients enrolled in the THALES study all have severe beta thalassemia genotypes that result in almost no endogenous beta globin production. The increases in fetal hemoglobin and presence of on-target indels in circulating blood cells suggests successful editing using zinc finger nucleases. The results are preliminary and will require additional patients and longer-term follow-up to assess their clinical significance, said Adrian Woolfson, BM., B.Ch., Ph.D., Head of Research and Development. It is important to note that myeloablative hematopoietic stem cell transplantation reboots the hematopoietic system, and that sufficient time is required for the stem cells to fully repopulate the marrow and for new blood cells to form. In other myeloablative conditioning studies in a similar patient population, full manifestation of the effects of gene modification in the red blood cell compartment has taken as long as 12 months or more to become evident.
Sanofis in vitro sickle cell disease poster details a similar approach to ST-400, using mobilized HSPCs from normal donors and SCD patients and utilizing the same zinc finger nuclease for gene editing, delivered as transient non-viral RNA, and designed to disrupt the erythroid specific enhancer of the BCL11A gene, which represses the expression of the gamma globin genes, thereby switching off HbF synthesis. Results from ex vivo studies demonstrated enriched biallelic editing, increased HbF, and reduced sickling in erythroid cells derived from non-treated sickle cell disease patients. Sanofi has initiated a Phase 1/2 trial evaluating BIVV003, an ex vivo gene-edited cell therapy using ZFN gene editing technology to modify autologous hematopoietic stem cells using fetal hemoglobin to produce functional red blood cells with higher BhF content that are resistant to sickling in patients with severe sickle cell disease. Recruitment is ongoing.
About the Alta study
The Phase 1/2 Alta study is an open-label, dose-ranging clinical trial designed to assess the safety and tolerability of SB-525 gene therapy in patients with severe hemophilia A. SB-525 was administered to 11 patients in 4 cohorts of 2 patients each across 4 ascending doses (9e11 vg/kg, 2e12 vg/kg, 1e13vg/kg and 3e13vg/kg) with expansion of the highest dose cohort by 3 additional patients. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug, Fast Track, and regenerative medicine advanced therapy (RMAT) designations to SB-525, which also received Orphan Medicinal Product designation from the European Medicines Agency.
About the THALES study
The Phase 1/2 THALES study is a single-arm, multi-site study to assess the safety, tolerability, and efficacy of ST-400 autologous hematopoietic stem cell transplant in 6 patients with transfusion-dependent beta thalassemia (TDT). ST-400 is manufactured by ex vivo gene editing of a patient's own (autologous) hematopoietic stem cells using non-viral delivery of zinc finger nuclease technology. The THALES study inclusion criteria include all patients with TDT (0/0 or non- 0/0) who have received at least 8 packed red blood cell transfusions per year for the two years before enrollment in the study. The FDA has granted Orphan Drug status to ST-400.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing, and gene regulation. For more information about Sangamo, visit http://www.sangamo.com.
This press release contains forward-looking statements regarding Sangamo's current expectations. These forward-looking statements include, without limitation, statements regarding the Company's ability to develop and commercialize product candidates to address genetic diseases with the Company's proprietary technologies, as well as the timing of commencement of clinical programs and the anticipated benefits therefrom. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the outcomes of clinical trials, the uncertain regulatory approval process, uncertainties related to the execution of clinical trials, Sangamo's reliance on partners and other third-parties to meet their clinical and manufacturing obligations, and the ability to maintain strategic partnerships. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo and its partners will be able to develop commercially viable product candidates. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo's operations and business environments. These risks and uncertainties are described more fully in Sangamo's Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission and Sangamo's most recent Quarterly Report on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.
- Jasper Therapeutics launches out of Stanford with new approach to stem cell treatment - Endpoints News - December 7th, 2019
- MaaT Pharma Announces the Presentation of Positive Data with Its Lead Microbiome Biotherapeutic in Intestinal-Predominant Acute... - December 7th, 2019
- Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers - GlobeNewswire - December 7th, 2019
- Sickle Cell Anemia Patient Becomes First Person in the US to Have Her Genes Edited With CRISPR - Interesting Engineering - December 7th, 2019
- Teen diagnosed with cancer again just months after being told he beat disease - Mirror Online - December 7th, 2019
- Ask the Doc! Check-ups and Stem Cell - Clay Co N.C. - Fetchyournews.com - December 7th, 2019
- The future of Ipsen's new $1.3B drug is in doubt as safety fears force the FDA to slam the brakes on late-stage studies - Endpoints News - December 7th, 2019
- Living with cancer: 'Exercising during my chemotherapy treatment worked wonders' - inews - December 7th, 2019
- Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis - Business Wire - December 7th, 2019
- Stem cells may trigger immune repair to mend hearts - BioNews - December 5th, 2019
- Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic... - December 5th, 2019
- Hunter Syndrome Treatment Market Size, Share & Trend Analysis By Treatment, By Region And Segment Forecasts, 2019 - 2026 - P&T Community - December 5th, 2019
- Platelet Rich Plasma and Stem Cell Alopecia Treatment Market is on Course to Expand at a CAGR of XX% Over the Forecast Period 2018 - 2026 - Weekly Spy - December 5th, 2019
- Cell-Easy Leads the Way Towards Tomorrow's Healthcare With Accessible Stem Cell Therapy - StreetInsider.com - December 5th, 2019
- Stem Cell Therapy for Diabetes and Related Conditions Market Size: Challenges to Industry Growth, Size, Share, Forecast 2025 - The Market Stats News - December 5th, 2019
- miR-194 Inhibits the Proliferation of SW620 Colon Cancer Stem Cells Th | CMAR - Dove Medical Press - December 5th, 2019
- Stem Cell Therapy Market Growth opportunities, Trends, Industry Analysis, and Forecast to 2020 - Kentucky Reports - December 5th, 2019
- Stem Cell Therapy for Multiple Sclerosis Capacity Production Cost Profit and Gross Margin Market Size Share Forecast to 2025 - The Market Stats News - December 5th, 2019
- As per new Study on Stem Cell Therapy Market 2019 Future Strategy, Analysis and Prediction by Leading Manufacturers, its Application and Types... - December 5th, 2019
- Stem Cell Therapy Market Size, Share, Trends, and Opportunity Analysis by 2017 - 2025 - The Market Expedition - December 5th, 2019
- Newly approved sickle cell drug ushers in an era of therapeutic breakthroughs - Worcester Telegram - December 5th, 2019
- A new stem cell therapy promises to heal injured heart - TheHealthSite - December 5th, 2019
- Harnessing Gamma T Cells To Bring Effective Therapies to Patients - Technology Networks - November 30th, 2019
- Phase 2 Trial Data on ALS NurOwn Therapy, Supporting Safety And Early Efficacy, Published - ALS News Today - November 30th, 2019
- Proof-of-Concept Study of CAR-NK Cell Therapy with Engineered Persistence Shows Potential - Cancer Network - November 29th, 2019
- Mum shares heartbreaking photo of toddler sobbing through gruelling cancer treatment - The Sun - November 29th, 2019
- Mesenchymal Stem Cells Market Key Trends, Key Players, Challenges And Standardization, Analysis Of Key Players, And Forecast To 2026 - WindStreetz - November 29th, 2019
- Bone Therapeutics SA: Information on the total number of voting rights and shares - GlobeNewswire - November 29th, 2019
- Induction Therapy and Hematopoietic Stem Cell Transplantation for Mixed-Phenotype Acute Leukemia - Cancer Therapy Advisor - November 28th, 2019
- Why Stem Cell Therapy Might Be Your Answer To Chronic Pain - Patch.com - November 28th, 2019
- North-east toddler overcomes cancer after pioneering stem cell treatment - Press and Journal - November 28th, 2019
- Man paralyzed from the neck down walks again thanks to a new medical innovation - GMA - November 28th, 2019
- Revolutionary stem cell banking and therapy from Celltex gives patients hope - KHOU.com - November 28th, 2019
- Kyoto University seeks approval to use stem cells in treatment for damaged knees - The Japan Times - November 28th, 2019
- Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy - Science Advances - November 28th, 2019
- Sickle Cell Disease: Current Treatment and Emerging Therapies - AJMC.com Managed Markets Network - November 28th, 2019
- Vertex plans major Boston expansion to support gene, cell therapy ambitions - FiercePharma - November 28th, 2019
- I almost died aged 23 then my sister became my stem cell donor - The Times - November 28th, 2019
- Discovery of 'Tendon Stem Cells' Could Revolutionize How We Recover From Injuries - Good News Network - November 28th, 2019
- You can take my Dads tweets over my dead body - TechCrunch - November 28th, 2019
- Global Stem Cell Therapy Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 - Avon Lake Ledger - November 28th, 2019
- From Tiger Woods to Brooks Koepka, the 9 things we learned this fall on PGA Tour - Golf Channel - November 28th, 2019
- Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Future Growth, Industry Verticals, and Research Forecast upto 2026 - The Denton Chronicle - November 28th, 2019
- Stem Cell Therapy Market Gain Impetus due to the Growing Demand over 2025 - Guru Online News - November 28th, 2019
- Stem Cell Therapy Market Size, by Therapeutic Application (Musculoskeletal Disorders, Wounds and Injuries), by Cell Source (Adipose Tissue-derived... - November 28th, 2019
- Global Musculoskeletal Disorder Stem Cell Therapy Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 - Avon Lake Ledger - November 28th, 2019
- Translink in Armagh holding stem cell registration event in memory of Gavin McNaney - Armagh i - November 28th, 2019
- Regenexx: Stem Cell Therapy & Platelet Rich Plasma for ... - November 25th, 2019
- Woman questions stem cell treatment advertised on radio after paying thousands with no pain relief - WBTV - November 25th, 2019
- Induction Therapy and Hematopoietic Stem Cell Transplantation for Mixed-Phenotype Acute Leukemia - Hematology Advisor - November 25th, 2019
- Tendon stem cell discovery could lead to improvements in injury recovery - Drug Target Review - November 25th, 2019
- 2 Small-Cap Biotechs That Soared Last Week - Motley Fool - November 25th, 2019
- Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre... - November 25th, 2019
- Cell Culture Market Size to Exceed US $42 Billion by 2026 - Post Register - November 25th, 2019
- Star Trek's William Shatner Receives Stem Cell Treatment to Restore his Youth - Magazine of Santa Clarita - November 25th, 2019
- AVITA Medical Teams With Gates Center to Advance Therapeutic Skin Restoration - CU Anschutz Today - November 25th, 2019
- New partnership aims to explore, cultivate innovations in cell and gene therapy - News-Medical.net - November 25th, 2019
- Outpatient ASCT for Myeloma Found Safe, Effective With Proper Patient Selection - Cancer Therapy Advisor - November 25th, 2019
- Seattle Genetics Announces Health Canada Approval of ADCETRIS (Brentuximab Vedotin) in Combination with Chemotherapy in Frontline CD30-Expressing... - November 25th, 2019
- Cell Isolation Market To Reach USD 18.26 Billion By 2026 | Reports And Data - GlobeNewswire - November 25th, 2019
- Partnership aims to accelerate cell and gene therapy - Harvard Gazette - November 25th, 2019
- Many stem cell clinics promise unapproved treatments: How to stay safe - NBC News - November 25th, 2019
- Prestigious NY Cancer Center Will Spend $3.7M To Study Bogus Cancer Treatment - Forbes - November 25th, 2019
- Buckley family thank community for support as thousands sign up to be a stem cell donor in three weeks - LeaderLive - November 25th, 2019
- My fight with blood cancer by musician to the stars - Henley Standard - November 25th, 2019
- Join the stem cell registry - Berea Mail - November 25th, 2019
- Give someone a chance to live by joining the stem cell registry | Daily News - Independent Online - November 25th, 2019
- Health: Botanix buddy set to benefit after DEA admits their synthetic CBD is probably ok - Stockhead - November 25th, 2019
- Molecular Therapy Family of Journals Welcomes Roland W. Herzog and Gerhard Bauer as Editors-in-Chief - PR Web - November 25th, 2019
- Massive Growth for Stem Cell Therapy Market 2019 Deep Analysis of Current Trends and Future Demand by Top Key Players Osiris Therapeutics, NuVasive,... - November 24th, 2019
- Solve Your Problem (Skin) With These Top-Rated Acne Products From Sephora - POPSUGAR - November 24th, 2019
- Celularity Presents Pre-Clinical Data Demonstrating the Potential of Allogeneic Placental-Derived, Cryopreserved NK Cell Therapy (CYNK-001) in... - November 22nd, 2019
- Allogene and the need for a reliable cell source - Vantage - November 22nd, 2019
- Full Alliance Group Announces New EBO2 Sites in Florida and the Caribbean - PRNewswire - November 22nd, 2019
- Autologous Stem Cell and Non Stem Cell Based Therapies Market Shares, Strategies, and Forecasts Analysis - Downey Magazine - November 22nd, 2019
- Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer -... - November 21st, 2019
- CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia - Business Wire - November 21st, 2019
- Brooks Koepka Withdraws From Presidents Cup Team - The New York Times - November 20th, 2019
- Rational discovery of antimetastatic agents targeting the intrinsically disordered region of MBD2 - Science Advances - November 20th, 2019
- Bristol-Myers Squibb Announces Update on CheckMate -915 for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo Alone in Patients with Resected... - November 20th, 2019